4.8 Article

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

A safe and potent anti-CD19 CAR T cell therapy

Zhitao Ying et al.

NATURE MEDICINE (2019)

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Review Chemistry, Multidisciplinary

Computational Modeling of Realistic Cell Membranes

Siewert J. Marrink et al.

CHEMICAL REVIEWS (2019)

Article Biochemistry & Molecular Biology

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Judith Feucht et al.

NATURE MEDICINE (2019)

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Review Hematology

Toxicities of CD19 CAR-T cell immunotherapy

Alexandre V. Hirayama et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Review Oncology

Chimeric antigen receptor T-cell therapies for lymphoma

Jennifer N. Brudno et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Review Oncology

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities

Sattva S. Neelapu et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Article Oncology

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates

Agne Taraseviciute et al.

CANCER DISCOVERY (2018)

Article Biotechnology & Applied Microbiology

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

Carlos A. Ramos et al.

MOLECULAR THERAPY (2018)

Review Cell Biology

Driving gene-engineered T cell immunotherapy of cancer

Laura A. Johnson et al.

CELL RESEARCH (2017)

Article Biotechnology & Applied Microbiology

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

James N. Kochenderfer et al.

MOLECULAR THERAPY (2017)

Article Medicine, General & Internal

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Cell & Tissue Engineering

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function

Nathan Singh et al.

CYTOTHERAPY (2017)

Review Medicine, Research & Experimental

CAR-T Cell Therapy for Lymphoma

Carlos A. Ramos et al.

ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)

Review Medicine, Research & Experimental

CAR therapy: the CD19 paradigm

Michel Sadelain

JOURNAL OF CLINICAL INVESTIGATION (2015)

Article Medicine, Research & Experimental

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

Barbara Savoldo et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

Article Oncology

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer et al.

JOURNAL OF IMMUNOTHERAPY (2009)

Article Oncology

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts

Renier J. Brentjens et al.

CLINICAL CANCER RESEARCH (2007)

Article Oncology

Revised response criteria for malignant lymphoma

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Review Endocrinology & Metabolism

Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes

G Meierhoff et al.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)